Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Q4 2018 Biomarin Pharmaceutical Inc Earnings Call Transcript

Feb 21, 2019 / 09:30PM GMT
Release Date Price: $97.3
Operator

Welcome to the BioMarin Fourth Quarter and Full Year 2018 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.

Traci McCarty
BioMarin Pharmaceutical Inc. - VP of IR

Thank you, Vincent. Thank you, everyone, for calling in today. From the management team at BioMarin, on the call is J.J. Bienaimé, Chairman and Chief Executive Officer; Hank Fuchs, President Worldwide Research and Development; Dan Spiegelman, Executive Vice President, Chief Financial Officer, Jeff Ajer, Executive Vice President, Chief Commercial Officer; and Robert Baffi, Executive Vice President, Technical Operations.

To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot